BACKGROUND: Despite increased access to highly active antiretroviral therapy (HAART), lung disease remains common in human immunodeficiency virus (HIV)-infected (HIV+) adolescents. There is limited information on changes in lung function over time in perinatally HIV+ adolescents on HAART. The objective was to investigate the progression of spirometry findings over 2 years in HIV+ adolescents on HAART in a prospective cohort, the Cape Town Adolescent Antiretroviral Cohort (CTAAC). METHODS: HIV+ adolescents aged 9-14 years, with at least 6 months of HAART, and a comparator group of healthy HIV-uninfected (HIV-), age-matched controls were enrolled in CTAAC. Spirometry and bronchodilator testing were done at baseline, 12 months, and 24 months. Mixed-effect models were used to compute longitudinal changes in lung function. RESULTS: Five hundred fifteen HIV+ adolescents, mean age 12 (standard deviation [SD], 1.6) years, 50.4% male, and 110 HIV- adolescents, mean age 11.8 (SD, 1.8) years, 45.6% male, were tested at baseline; 477 (93%) HIV+ and 102 (93%) HIV- adolescents at 12 months; and 473 (92%) HIV+ and 97 (88%) HIV- adolescents at 24 months. Only 5.4% of the HIV+ adolescents had HIV viral load >10 000 copies/mL at baseline. Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were lower in the HIV+ compared to the HIV- adolescents and tracked with no deterioration or catch-up over 2 years. Previous pulmonary tuberculosis (PTB) or lower respiratory tract infection (LRTI) was significantly associated with reduced FEV1 and FVC (P < .05 for both). CONCLUSIONS: HIV+ adolescents had lower lung function over 2 years than HIV- adolescents. This study highlights the need for lung function surveillance and prevention of LRTIs and PTB in HIV+ adolescents.
BACKGROUND: Despite increased access to highly active antiretroviral therapy (HAART), lung disease remains common in human immunodeficiency virus (HIV)-infected (HIV+) adolescents. There is limited information on changes in lung function over time in perinatally HIV+ adolescents on HAART. The objective was to investigate the progression of spirometry findings over 2 years in HIV+ adolescents on HAART in a prospective cohort, the Cape Town Adolescent Antiretroviral Cohort (CTAAC). METHODS: HIV+ adolescents aged 9-14 years, with at least 6 months of HAART, and a comparator group of healthy HIV-uninfected (HIV-), age-matched controls were enrolled in CTAAC. Spirometry and bronchodilator testing were done at baseline, 12 months, and 24 months. Mixed-effect models were used to compute longitudinal changes in lung function. RESULTS: Five hundred fifteen HIV+ adolescents, mean age 12 (standard deviation [SD], 1.6) years, 50.4% male, and 110 HIV- adolescents, mean age 11.8 (SD, 1.8) years, 45.6% male, were tested at baseline; 477 (93%) HIV+ and 102 (93%) HIV- adolescents at 12 months; and 473 (92%) HIV+ and 97 (88%) HIV- adolescents at 24 months. Only 5.4% of the HIV+ adolescents had HIV viral load >10 000 copies/mL at baseline. Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were lower in the HIV+ compared to the HIV- adolescents and tracked with no deterioration or catch-up over 2 years. Previous pulmonary tuberculosis (PTB) or lower respiratory tract infection (LRTI) was significantly associated with reduced FEV1 and FVC (P < .05 for both). CONCLUSIONS: HIV+ adolescents had lower lung function over 2 years than HIV- adolescents. This study highlights the need for lung function surveillance and prevention of LRTIs and PTB in HIV+ adolescents.
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: R Masekela; R Anderson; T Moodley; O P Kitchin; S M Risenga; P J Becker; R J Green Journal: Int J Tuberc Lung Dis Date: 2012-01 Impact factor: 2.373
Authors: Michele Arigliani; Mario C Canciani; Giovanni Mottini; Michele Altomare; Andrea Magnolato; Sofia Vanda Loa Clemente; Leon Tshilolo; Paola Cogo; Philip H Quanjer Journal: Am J Respir Crit Care Med Date: 2017-01-15 Impact factor: 21.405
Authors: Kathryn J Snow; Lisa J Nelson; Charalambos Sismanidis; Susan M Sawyer; Stephen M Graham Journal: Epidemiol Infect Date: 2018-04-15 Impact factor: 4.434
Authors: Rashida A Ferrand; Grace McHugh; Andrea M Rehman; Hilda Mujuru; Victoria Simms; Edith D Majonga; Mark P Nicol; Trond Flaegstad; Tore J Gutteberg; Carmen Gonzalez-Martinez; Elizabeth L Corbett; Sarah L Rowland-Jones; Katharina Kranzer; Helen A Weiss; Jon O Odland Journal: JAMA Netw Open Date: 2020-12-01
Authors: Amy Price; Grace McHugh; Victoria Simms; Robina Semphere; Lucky G Ngwira; Tsitsi Bandason; Hilda Mujuru; Jon O Odland; Rashida A Ferrand; Andrea M Rehman Journal: EClinicalMedicine Date: 2021-11-13
Authors: Andre Gie; Julie Morrison; David Maree; Barbara Laughton; Sara H Browne; Mark F Cotton; Pierre Goussard; Steve Innes Journal: ERJ Open Res Date: 2022-03-21
Authors: Alexander W Kay; Helena Rabie; Elizabeth Maleche-Obimbo; Moorine Penninah Sekadde; Mark F Cotton; Anna M Mandalakas Journal: Pathogens Date: 2021-12-29